Surrozen (SRZN) Corporate presentation summary

Market opportunity and unmet needs

• Retinal vascular diseases like DME and wet AMD affect over 40 million globally, with a US prevalence of 2.3 million and a projected market growth from $14B in 2025 to $19B in 2035.

• Current anti-VEGF therapies are widely used but have limitations in treatment durability and efficacy, creating demand for better and longer-lasting options.

• Key unmet needs include improved drying agents, longer-lasting therapies, and new mechanisms beyond VEGF inhibition.

Scientific and clinical innovation

• Wnt signaling is validated as a key regulator of retinal vascular function, restoring blood-retina barrier integrity and reducing leakage.

• Combining Wnt agonism with VEGF inhibition shows synergistic effects in preclinical models, outperforming monotherapies.

• SZN-8141 and SZN-8143 are next-generation multifunctional antibodies targeting Wnt, VEGF, and IL-6 pathways for enhanced efficacy.

Pipeline and clinical development

• SZN-8141 combines Wnt activation and VEGF inhibition, restoring vessel architecture and reducing avascular and neovascular areas in preclinical models.

• SZN-8143 adds IL-6 inhibition, aiming to further reduce vascular permeability and VEGF production.

• The DUET Phase 1b/2a study for SZN-8141 in DME will initiate by year-end 2026, with initial data expected in the second half of 2027.